- Triples Facility Size to Accommodate Growth -
- Includes Expanded and Technologically Advanced Theatre to Accelerate Surgeon Adoption -
SAN DIEGO, Jan. 24 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today its relocation to an expanded state-of-the-art facility to accommodate future growth and the accelerating demand for surgeon education and training on its non-invasive spine surgery.
The three-story, leased building is located in San Diego and triples the Company's available space to 62,367 square feet. Conveniently situated in the Towne Centre Technology Park, this facility provides additional capacity to accommodate the warehousing and distribution of products, instrument sets and implants. It also triples our fabrication capabilities for instrument prototyping and it enhances our Absolute Responsiveness program to customers by providing custom features to their specifications.
The facility houses an expanded Cadaver Operating Theatre comprised of six surgical suites for the training of surgeons and sales representatives. The operating theater has been equipped with the state-of-the-art surgical and technological advancements, ensuring the most accurate and precise training experience using the Company's MAS(TM) platform.
Alexis V. Lukianov, Chairman and Chief Executive Officer, remarked, "The continued momentum in surgeon adoption of our leading spine surgery products and technologies demands the increased warehousing, training and distribution capacity this new headquarters provides. We are particularly excited about our enhanced and expanded Cadaver Operating Theatre. It enables us to train six individual surgeons simultaneously and up to 24 surgeons in a classroom format. We believe our theatre is the finest corporate on-site spine training facility in the United States today."
As of January 24, 2005 the Company's new headquarters address and main telephone number will be:
4545 Towne Centre Court
San Diego, CA 92121
toll free: 800-455-1476
NuVasive is a medical device company focusing on the design, development and marketing of products for use in minimally disruptive surgical treatments for the spine. NuVasive's Maximum Access Surgery (MAS(TM)) product platform includes the NeuroVision(R) nerve avoidance system, MaXcess(TM) spine access system, and specialized implants. NuVasive also offers classic fusion implant products for use in spine surgery and has an R&D pipeline emphasizing motion preservation products such as total disc replacement (TDR).
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "planned," "expects," "believes," "strategy," "opportunity," "anticipates" and similar words. These statements may include, among others, plans, strategies and objectives of management for future operations; any statements regarding proposed new products, services or developments; any statements regarding future economic conditions or financial or operating performance; statements of belief and any statements of assumptions underlying any of the foregoing. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to, the rapidly changing and competitive nature of the medical device industry, NuVasive's ability to convince surgeons to use its products, the ability of patients to obtain third-party reimbursement for surgical procedures employing NuVasive's products, risks related to government regulation of medical devices, risks related to NuVasive's ability to effectively manage the growth of its business, risks related to ownership and enforcement of intellectual property rights, NuVasive's ability to successfully develop new products, and other risks and uncertainties more fully described in NuVasive's Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and NuVasive's Prospectus filed pursuant to Rule 424 under the Securities Act of 1933, as amended, with the Securities and Exchange Commission on May 13, 2004. NuVasive's public filings with the Securities and Exchange Commission are available at http://www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Kevin C. O'Boyle
EVP & Chief Financial Officer
Stephanie Carrington/Greg Tiberend
The Ruth Group